Treatment of traumatic brain injury with vepoloxamer

维泊洛沙姆治疗颅脑损伤

基本信息

  • 批准号:
    9814366
  • 负责人:
  • 金额:
    $ 32.92万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-06-01 至 2024-05-31
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY/ABSTRACT Traumatic brain injury (TBI) is a major cause of death and disability worldwide. There are no effective therapies available for TBI patients. Thus, there is a compelling need to develop novel therapeutics in order to improve neurological recovery after TBI. Among many secondary injury events that occur after TBI, cerebral microthrombosis is an under-recognized, yet important contributor to the secondary brain ischemia and damage that occurs after TBI, and would therefore seem to be one of the central secondary events after brain trauma to bear in mind when designing treatment strategies. Cerebral microthrombi not only lead to ischemia and cell death but also prevent therapeutic drugs from entering into the affected brain and therefore constrain the efficacy of therapeutic drugs, which may be one of important factors ignored during preclinical and clinical trials. Our recent study indicates that early (2 hours post injury) intravenous administration of Vepoloxamer promotes sensorimotor function and cognitive functional recovery after TBI induced by controlled cortical impact (CCI-TBI), which is associated with its robust effect on reducing cerebral microthrombosis formation and neuroinflammation. Vepoloxamer is a purified form of Poloxamer 188 where impurities associated with renal dysfunction have been removed, which is an amphiphilic polyethylene-polypropylene-polyethylene tri-block copolymer that is reported to seal membranes and restore plasma membrane integrity in damaged cells. However, to date, there is a paucity of information about Vepoloxamer for treatment of TBI and the mechanisms underlying its therapeutic effects. von Willebrand factor (vWF) released into blood from injured endothelial cells inversely correlates with clinical outcome of severe TBI. vWF can induce microthrombosis formation. Our previous study demonstrated that the level of vWF released into plasma increases at 1-4 hours, peaks at 1-3 days, declines at 8 days, and returns to normal at 15 days in rats after CCI-TBI. We hypothesize that TBI induces the blood-brain barrier (BBB) damage and release of endothelial-derived vWF, which leads to platelet aggregate and subsequent cerebral microthrombosis-induced secondary injury. In Aim 1, we will first conduct a dose-finding study to identify Vepoloxamer dose and therapeutic window effect on functional recovery without toxicity in young rats (male and female) with TBI. In Aim 2, we will then investigate the mechanisms by which IV administration of Vepoloxamer enhances cerebral microvascular perfusion and promotes functional recovery after TBI. Microvascular integrity, cerebral blood flow, and BBB leakage will be measured dynamically using either laser scanning confocal microscopy or magnetic resonance imaging (MRI). This work will address a previously understudied important issue and is highly translational. Successful completion of this proposed research will elucidate mechanisms underlying IV Vepoloxamer-mediated promotion of TBI recovery, and facilitate development of Vepoloxamer as a novel therapeutic approach targeting endothelial cells/microthrombi to improve neurological outcome for TBI patients.
项目摘要/摘要 创伤性脑损伤是世界范围内死亡和致残的主要原因。目前还没有有效的治疗方法 适用于脑外伤患者。因此,迫切需要开发新的治疗方法,以改善 颅脑损伤后神经功能恢复情况。在颅脑损伤后发生的许多继发性损伤事件中,脑部 微血栓形成是继发性脑缺血和损伤的重要因素,但尚未得到充分认识。 这发生在脑外伤后,因此似乎是脑创伤后的中心继发性事件之一。 设计治疗策略时要牢记这一点。脑微血栓不仅导致脑缺血和细胞 死亡,但也阻止治疗药物进入受影响的大脑,从而限制 治疗药物的疗效,这可能是临床前和临床试验中被忽视的重要因素之一。 我们最近的研究表明,早期(受伤后2小时)静脉注射维泊洛沙姆可促进 控制性皮质撞击致颅脑损伤后感觉运动功能和认知功能恢复 (CCI-TBI),这与其在减少脑微血栓形成和 神经炎。维泊洛沙姆是泊洛沙姆188的一种纯化形式,其中与肾脏相关的杂质 功能已被去除,这是一种两亲性的聚乙烯-聚丙烯-聚乙烯三嵌段 据报道,这种共聚物可以密封细胞膜,恢复受损细胞的质膜完整性。 然而,到目前为止,关于维泊洛沙姆治疗颅脑损伤及其机制的信息还很少。 潜在的治疗效果。血管性血友病因子(VWF)从受损内皮细胞释放到血液中 与重型颅脑损伤的临床转归呈负相关。VWF可诱导微血栓形成。我们的 先前的研究表明,vWF释放到血浆中的水平在1-4小时内增加,在1-3小时达到峰值 大鼠CCI-TBI后8天开始下降,15天恢复正常。我们假设TBI 诱导血脑屏障损伤,释放内皮源性vWF,导致血小板 聚集体和随后的脑微血栓形成导致的继发性损伤。在目标1中,我们将首先进行 剂量发现研究确定维泊洛沙姆的剂量和治疗窗对功能恢复的影响 脑外伤幼鼠(雌雄)的毒性。在目标2中,我们将研究IV 维泊洛沙姆增强脑微血管灌注促进功能恢复 在TBI之后。微血管完整性、脑血流量和血脑屏障渗漏将使用 激光扫描共聚焦显微镜或磁共振成像(MRI)。这项工作将解决一个 以前对重要问题的研究不足,具有很高的翻译性。圆满完成这项建议 研究将阐明静脉维泊洛沙姆促进创伤性脑损伤恢复的潜在机制,以及 促进维泊洛沙姆作为靶向内皮细胞/微血栓的新治疗方法的开发 目的:改善脑外伤患者的神经预后。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Yanlu Zhang其他文献

Yanlu Zhang的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Yanlu Zhang', 18)}}的其他基金

Treatment of traumatic brain injury with vepoloxamer
维泊洛沙姆治疗颅脑损伤
  • 批准号:
    10418779
  • 财政年份:
    2019
  • 资助金额:
    $ 32.92万
  • 项目类别:
Treatment of traumatic brain injury with vepoloxamer
维泊洛沙姆治疗颅脑损伤
  • 批准号:
    10621791
  • 财政年份:
    2019
  • 资助金额:
    $ 32.92万
  • 项目类别:

相似海外基金

How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
  • 批准号:
    BB/Z514391/1
  • 财政年份:
    2024
  • 资助金额:
    $ 32.92万
  • 项目类别:
    Training Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
  • 批准号:
    2312555
  • 财政年份:
    2024
  • 资助金额:
    $ 32.92万
  • 项目类别:
    Standard Grant
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
  • 批准号:
    2327346
  • 财政年份:
    2024
  • 资助金额:
    $ 32.92万
  • 项目类别:
    Standard Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
  • 批准号:
    ES/Z502595/1
  • 财政年份:
    2024
  • 资助金额:
    $ 32.92万
  • 项目类别:
    Fellowship
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
  • 批准号:
    23K24936
  • 财政年份:
    2024
  • 资助金额:
    $ 32.92万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
  • 批准号:
    ES/Z000149/1
  • 财政年份:
    2024
  • 资助金额:
    $ 32.92万
  • 项目类别:
    Research Grant
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
  • 批准号:
    2901648
  • 财政年份:
    2024
  • 资助金额:
    $ 32.92万
  • 项目类别:
    Studentship
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
  • 批准号:
    488039
  • 财政年份:
    2023
  • 资助金额:
    $ 32.92万
  • 项目类别:
    Operating Grants
New Tendencies of French Film Theory: Representation, Body, Affect
法国电影理论新动向:再现、身体、情感
  • 批准号:
    23K00129
  • 财政年份:
    2023
  • 资助金额:
    $ 32.92万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
The Protruding Void: Mystical Affect in Samuel Beckett's Prose
突出的虚空:塞缪尔·贝克特散文中的神秘影响
  • 批准号:
    2883985
  • 财政年份:
    2023
  • 资助金额:
    $ 32.92万
  • 项目类别:
    Studentship
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了